Highlights Landos Biopharma, Inc.

Equities

Delayed Nasdaq Other stock markets 16:00:00 2024-05-23 EDT			5-day change	1st Jan Change
22.93 ^USD	+0.58%		-.--%	+526.50%

06-13	AbbVie inks immune disorder drug licensing deal with China's FutureGen	RE
05-24	Landos Biopharma, Inc.(NasdaqCM:LABP) dropped from S&P TMI Index	CI

AbbVie inks immune disorder drug licensing deal with China's FutureGen	06-13	RE
AbbVie Completes Acquisition of Landos Biopharma	05-23	MT
Landos Biopharma, Inc. Announces Board and Executive Changes	05-23	CI
AbbVie Inc. completed the acquisition of Landos Biopharma, Inc. from a group of shareholders.	05-22	CI
Landos Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
North American Morning Briefing : Stocks Seen -2-	04-02	DJ
Deals of the day-Mergers and acquisitions	03-25	RE
Sector Update: Health Care Stocks Decline Late Afternoon	03-25	MT
Top Midday Gainers	03-25	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	03-25	MT
AbbVie to Acquire Landos Biopharma For About $137.5 Million; Landos Shares Jump	03-25	MT
Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie	03-25	DJ
AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million	03-25	DJ
AbbVie to Acquire Landos Biopharma for About $137.5 Million	03-25	MT
AbbVie to Acquire Landos Biopharma for About $137.5 Million	03-25	MT
AbbVie to buy Landos to expand pipeline of immunity-related illnesses	03-25	RE
AbbVie Inc. agreed to acquire Landos Biopharma, Inc. on March 24, 2024.	03-24	CI
Landos Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Landos Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
Landos Biopharma, Inc. Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn?s and Colitis	11-21	CI

No results for this search